Welcome to our dedicated page for Mirati Therapeutics news (Ticker: MRTX), a resource for investors and traders seeking the latest updates and insights on Mirati Therapeutics stock.
Mirati Therapeutics, Inc. (NASDAQ: MRTX) is a commercial stage biotechnology company focused on pioneering breakthrough therapies to transform the lives of patients with cancer. Specializing in molecularly targeted and immuno-oncology combination therapies, Mirati is at the forefront of cancer treatment innovation. The core of Mirati's mission is to develop drug candidates that target genetic and epigenetic drivers of cancer. The company leverages a strategic approach that includes selecting patients whose tumors depend on specific genetic alterations and employing a highly accomplished leadership team in oncology precision medicine.
Mirati Therapeutics is advancing three primary drug candidates through clinical development for multiple oncology indications. Their flagship product, KRAZATI® (adagrasib), has shown promising results in treating non-small cell lung cancer (NSCLC) harboring the KRASG12C mutation. Adagrasib offers potential best-in-class efficacy, particularly for patients with central nervous system metastases. Notably, the drug has been granted conditional marketing authorization by the UK's MHRA and the European Commission, highlighting its impactful role in current cancer treatment paradigms.
Mirati's innovative pipeline also includes MRTX1719, a PRMT5 inhibitor, and MRTX1133, a selective KRASG12D inhibitor, both of which are designed to address high unmet medical needs. The company recently completed an upsized public offering, extending its cash runway to support upcoming milestones.
In recent developments, Mirati announced that Laurie Stelzer, Chief Financial Officer, will depart the company in September 2023, with Aaron Ondrey stepping in as interim CFO. This transition comes at a pivotal time as Mirati continues to advance its clinical programs and prepare for potential new product launches.
With a relentless focus on patient outcomes, Mirati's vision is to unlock the science behind a life beyond cancer. The company continues to collaborate with global healthcare regulators and partners to ensure broad access to its groundbreaking therapies.
Mirati Therapeutics (NASDAQ: MRTX) will participate in a fireside chat at the Stifel Healthcare Conference 2021 on November 16 at 8:20 a.m. PT. The session will feature David Meek, CEO, and Charles Baum, M.D., Ph.D., President. The event will be webcasted and accessible via the Investors and Media section on Mirati.com, with a replay available post-event. Mirati focuses on developing innovative cancer therapies, including adagrasib (MRTX849) and sitravatinib.
Mirati Therapeutics (NASDAQ: MRTX) reported Q3 2021 financial results, revealing a net loss of $80.1 million, or $1.55 per share, improved from a loss of $87.3 million last year. The company ended the quarter with $1.2 billion in cash. Key updates include progress on adagrasib for KRASG12C-mutated lung cancer, with FDA NDA submission expected by year-end. Positive preliminary Phase 1b results show a 100% disease control rate in patients treated with adagrasib and pembrolizumab. The pipeline includes further developments in sitravatinib and MRTX1719, with continued advancements in clinical trials.
Mirati Therapeutics, Inc. (NASDAQ: MRTX) will report its financial results for Q3 2021 on November 8 at 4:30 p.m. ET. The announcement will include corporate updates alongside financial results during a conference call. Investors can join the call via a live webcast or by phone. Mirati focuses on developing breakthrough therapies for cancer, particularly targeting KRAS mutations with investigational drugs like adagrasib (MRTX849) and sitravatinib. The company emphasizes addressing significant unmet needs in oncology.
Mirati Therapeutics (NASDAQ: MRTX) announced a clinical collaboration with Sanofi to evaluate the combination of adagrasib, a KRASG12C inhibitor, with Sanofi's SAR442720 (RMC-4630), an SHP2 inhibitor. This Phase 1/2 study will focus on patients with previously-treated non-small cell lung cancer (NSCLC) harboring KRASG12C mutations. The collaboration aims to optimize clinical outcomes and shares study costs. Mirati is advancing a robust development program for adagrasib, targeting high unmet needs in oncology.
Mirati Therapeutics (NASDAQ: MRTX) announced new clinical and preclinical research to be presented at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics from October 7-10, 2021. Key presentations include:
- MRTX1719: First-in-class PRMT5 inhibitor for MTAP-deleted cancers.
- MRTX1133: KRASG12D inhibitor with promising preclinical data.
- Adagrasib: Data from KRYSTAL-1 trial on KRASG12C-mutated pancreatic cancer.
Mirati focuses on innovative therapies targeting genetic and immunological cancer drivers.
Mirati Therapeutics, Inc. (NASDAQ: MRTX) announced an inducement stock option grant to newly appointed CEO David Meek, allowing him to purchase 150,300 shares at an exercise price of $167.10. The stock options will vest over four years, with the first 25% vesting after one year. This grant is compliant with NASDAQ Listing Rule 5635(c)(4) and aims to align Mr. Meek's interests with that of the shareholders. Mirati is focused on developing therapies for cancer, particularly targeting KRAS mutations and receptor tyrosine kinases.
Mirati Therapeutics (MRTX) has appointed David Meek as its new Chief Executive Officer (CEO) effective immediately. He joins the Board of Directors, succeeding Charles M. Baum, who remains as President and head of R&D. Mr. Meek brings over 30 years of industry experience, notably leading Ipsen as CEO. Under his leadership, Mirati aims to advance its oncology pipeline, including the adagrasib and sitravatinib therapies with IND submissions anticipated in Q4 2021. The leadership transition is expected to build upon Mirati's commitment to targeted cancer therapies.
Mirati Therapeutics (NASDAQ: MRTX) reported positive topline results from the Phase 2 KRYSTAL-1 study for adagrasib, targeting advanced non-small cell lung cancer (NSCLC) with the KRASG12C mutation. The study showed an objective response rate (ORR) of 43% and a disease control rate of 80% among patients with a median follow-up of 9 months. With plans for a New Drug Application submission by Q4 2021, the findings bolster confidence in adagrasib as a promising therapy. Additionally, updated Phase 1 findings revealed an ORR of 58% in a smaller cohort.
Mirati Therapeutics (NASDAQ: MRTX) announced positive results from the Phase 1/2 KRYSTAL-1 study of adagrasib in patients with KRASG12C-mutated colorectal cancer. The monotherapy arm showed a response rate of 22% and a disease control rate of 87%. In combination with cetuximab, the response rate rose to 43%, with 100% disease control in evaluable patients. The study demonstrated a manageable safety profile with no Grade 5 treatment-related adverse events. These findings will support further evaluation in ongoing studies, including a Phase 3 trial.
FAQ
What is the market cap of Mirati Therapeutics (MRTX)?
What does Mirati Therapeutics specialize in?
What are the main drug candidates of Mirati Therapeutics?
What recent approvals has KRAZATI® received?
Who is the interim Chief Financial Officer of Mirati Therapeutics?
What is the focus of Mirati's drug development strategy?
Where can I find more information about Mirati's clinical trials?
How does Mirati's adagrasib (KRAZATI) differ from other cancer treatments?
What recent corporate updates has Mirati announced?
What is the mission of Mirati Therapeutics?
How can investors contact Mirati Therapeutics?
